Toceranib phosphate (Standard)
Toceranib phosphate (Standard) is the analytical standard of Toceranib phosphate (HY-10330A). This product is intended for research and analytical applications. Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors .
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 874819-74-6
- Formel: C22H28FN4O6P
- Molecular Weight:494.45
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Reinheit & Dokumentation
-
Help & FAQs
-
HY-10330A
Toceranib phosphateRTK Inhibitor -
HY-13223
CrenolanibFLT3 Inhibitor -
HY-10330
ToceranibRTK Inhibitor -
HY-10255A
SunitinibMulti-targeted RTK Inhibitor -
HY-50904
NintedanibPDGFR/VEGFR/FGFR Inhibitor -
HY-10208
PazopanibVEGFR Inhibitor -
HY-15463
ImatinibTyrosine Kinases Inhibitor -
HY-15506
TAK-593VEGFR/PDGFR Inhibitor -
HY-109019
VorolanibVEGFR/PDGFR Inhibitor -
HY-11106
Nintedanib esylatePDGFR/VEGFR/FGFR Inhibitor -
HY-10407
SU 5402Tyrosine Kinase Inhibitor -
HY-12050
CP-673451PDGFR Inhibitor
Product Information
Information
Anwendung
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS. Nr. 874819-74-6
-
Molecular Weight 494.45
-
Formel C22H28FN4O6P
-
SMILES
O=C(NCCN1CCCC1)C2=C(NC(/C=C3C(NC4=C\3C=C(C=C4)F)=O)=C2C)C.O=P(O)(O)O
-
Synonyms
SU11654 phosphate (Standard); PHA 291639E phosphate (Standard)
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. London CA, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res. 2003 Jul;9(7):2755-68. [Content Brief]
[2]. Halsey CH, et al. Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia?) in canine mast cell tumor. BMC Vet Res. 2014 May 6;10:105. [Content Brief]
[3]. Mitchell L, et al. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. J Vet Intern Med. 2012 Mar-Apr;26(2):355-62. [Content Brief]
[4]. London C, Mathie T, Stingle N, et al. Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours. Vet Comp Oncol. 2012;10(3):194-205. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Toceranib phosphate (Standard) Related Classifications
HY-10330AR Related Classifications
Powered by Bioz